Patient clinical and demographic characteristics
Patient no. . | Cytogenetics . | AML type . | Age, y . | Sex . | Race . | Outcome . | Other comments . |
---|---|---|---|---|---|---|---|
1 | Complex, including Inv16 | De novo | 44 | Male | White | Relapsed | |
2 | Inv16 and +8 | Treatment-related | 64 | Female | White | CRp | |
3 | Inv16 and +22 | De novo | 50 | Female | White | CR | |
4 | Inv16 and +8 | De novo | 23 | Female | White | CR | |
5 | Inv16 | De novo | 58 | Female | Black | Relapsed | |
6 | Inv16 and FLT3 D835 (constitutional 47, XXY) | De novo | 40 | Male | White | Died | Died during induction |
7* | t(8;21) | Treatment-related | 51 | Female | White | Relapsed | |
8 | t(8;21) and FLT3 D835 | De novo | 54 | Male | White | Relapsed | Did not receive consolidation |
9 | t(8;21) | De novo | 24 | Male | Hispanic | Relapsed | |
10 | t(8;21) | De novo | 27 | Male | Asian | CR | |
11 | t(8;21) and del 12p | De novo | 49 | Male | White | CR | |
12 | +21 | Treatment-related MDS/AML | 64 | Male | White | Died | Died of infection while relapsing |
13 | +11 | CMML/AML | 54 | Male | White | CR | |
14* | Normal | De novo | 44 | Female | White | Relapsed | CR2 after allogeneic transplantation |
15* | Complex, including +21 | Treatment-related MDS/AML | 64 | Female | White | Relapsed | Probable constitutional +X |
16* | Complex, including del 7q | De novo | 34 | Female | Asian | CR | s/p allogeneic transplantation |
17 | Normal | De novo | 54 | Male | White | CRp | |
18 | Normal with FLT3 D835 | De novo | 69 | Male | White | Relapsed | 3/20 metaphases with +13 |
19* | t(8;21) and del Y | De novo | 49 | Male | White | CR | |
20* | t(8;21) | De novo | 55 | Male | Black | CR | |
21* | Normal | De novo | 48 | Male | White | CRi | |
22 | Inv16 and FLT3 D835 | De novo | 38 | Male | White | CR | |
23 | Normal | De novo | 61 | Male | Black | Primary Refractory | |
24 | Normal with FLT3 ITD | De novo | 21 | Female | White | Primary refractory | |
25 | Complex, including del 5 and del 7 | De novo | 57 | Male | White | Primary refractory | |
26 | t(9;11) and +8 | De novo | 58 | Female | Black | Relapsed | CD34− leukemia |
27 | +8, FLT3 ITD, and NPM1 | De novo | 58 | Female | Black | CR | CD34− leukemia |
Patient no. . | Cytogenetics . | AML type . | Age, y . | Sex . | Race . | Outcome . | Other comments . |
---|---|---|---|---|---|---|---|
1 | Complex, including Inv16 | De novo | 44 | Male | White | Relapsed | |
2 | Inv16 and +8 | Treatment-related | 64 | Female | White | CRp | |
3 | Inv16 and +22 | De novo | 50 | Female | White | CR | |
4 | Inv16 and +8 | De novo | 23 | Female | White | CR | |
5 | Inv16 | De novo | 58 | Female | Black | Relapsed | |
6 | Inv16 and FLT3 D835 (constitutional 47, XXY) | De novo | 40 | Male | White | Died | Died during induction |
7* | t(8;21) | Treatment-related | 51 | Female | White | Relapsed | |
8 | t(8;21) and FLT3 D835 | De novo | 54 | Male | White | Relapsed | Did not receive consolidation |
9 | t(8;21) | De novo | 24 | Male | Hispanic | Relapsed | |
10 | t(8;21) | De novo | 27 | Male | Asian | CR | |
11 | t(8;21) and del 12p | De novo | 49 | Male | White | CR | |
12 | +21 | Treatment-related MDS/AML | 64 | Male | White | Died | Died of infection while relapsing |
13 | +11 | CMML/AML | 54 | Male | White | CR | |
14* | Normal | De novo | 44 | Female | White | Relapsed | CR2 after allogeneic transplantation |
15* | Complex, including +21 | Treatment-related MDS/AML | 64 | Female | White | Relapsed | Probable constitutional +X |
16* | Complex, including del 7q | De novo | 34 | Female | Asian | CR | s/p allogeneic transplantation |
17 | Normal | De novo | 54 | Male | White | CRp | |
18 | Normal with FLT3 D835 | De novo | 69 | Male | White | Relapsed | 3/20 metaphases with +13 |
19* | t(8;21) and del Y | De novo | 49 | Male | White | CR | |
20* | t(8;21) | De novo | 55 | Male | Black | CR | |
21* | Normal | De novo | 48 | Male | White | CRi | |
22 | Inv16 and FLT3 D835 | De novo | 38 | Male | White | CR | |
23 | Normal | De novo | 61 | Male | Black | Primary Refractory | |
24 | Normal with FLT3 ITD | De novo | 21 | Female | White | Primary refractory | |
25 | Complex, including del 5 and del 7 | De novo | 57 | Male | White | Primary refractory | |
26 | t(9;11) and +8 | De novo | 58 | Female | Black | Relapsed | CD34− leukemia |
27 | +8, FLT3 ITD, and NPM1 | De novo | 58 | Female | Black | CR | CD34− leukemia |
CRp indicates CR with incomplete platelet recovery; CRi, CR with incomplete count recovery; MDS, myelodysplasia; S/P, status post; and CMML, chronic myelomonocytic leukemia.
No specimen from initial diagnosis.